36 results about "Aging-associated diseases" patented technology

The present invention relates to a composition of a thiazolium compound of formula I or a solvate thereof, wherein the definitions of groups in the formula I are as those given in the claims:

The invention relates to a pharmaceutical composition with an anti-aging effect. The pharmaceutical composition is prepared from the following monomer compounds in parts by weight: 12-18 parts of 7,2'-dyhydroxy-3',4'-dimethoxyisofiavanone, 9-14 parts of (6aR, 11aR)-9,10-dimethoxy pterocarpan-3-oxo-beta-D-glucoside, 6-10 parts of formononetin, 7-11 parts of formononetin-7-oxo-beta-D-glucoside, 20-30 parts of calycosin and 20-30 parts of calycosin-7-oxo-beta-D-glucoside. Compared with the prior art, the pharmaceutical composition disclosed by the invention has the effects of significantly prolonging life, can be used for preventing and treating aging-related diseases such as senile dementia, cardiovascular diseases and diabetes, and can be applied to the field of health foods.

The present invention relates to a composition of a thiazolium compound of formula I or a solvate thereof, wherein the definitions of groups in the formula I are as those given in the claims:

Provided are anti-aging and anti-inflammatory prodrugs designed from cytotoxic agents incorporated into sites that can be cleaved by SA-beta-gal after delivery of the prodrug in vivo by chemically modifying the cytotoxic agents to release the active parent drug. The prodrugs include a galactosyl moiety, a benzyloxycarboxyl moiety, and a cytotoxic agent moiety, which are preferably acetylated. An anti-aging prodrug for selectively killing one or more senescent cells and / or reducing acute or chronic inflammatory responses in a subject in need thereof is administered to the subject in a therapeutically effective amount of the anti-aging prodrug. The disclosed compositions are useful for reducing one or more symptoms associated with an aging-related disease or disorder or an inflammatory disorder, such as virus-mediated inflammation, in a subject.

The invention relates to an application of a Baz2b gene as a target spot in senescence alleviation and discloses that the Baz2b gene plays an important role in regulating and controlling the occurrence and development of normal senescence and senescence-related diseases, and the down-adjustment of the Baz2b gene can obviously relieve senescence and improve memory degeneration, behavioral ability degeneration and the like in the senescence process. Therefore, the Baz2b can be used as a research target of senescence and senescence-related diseases, can be used for developing medicines for inhibiting or delaying senescence, and can be used as a marker for diagnosis and prognosis evaluation of senescence and senescence-related diseases.

The invention discloses the application of mPGES‑2 as a drug target for preventing and / or treating aging diseases. The present invention proposes for the first time that mPGES‑2 is a drug target for doxorubicin and hydrogen peroxide-induced senescence. Experiments have shown that mPGES‑2 knockout can significantly prolong the lifespan of doxorubicin-induced aging mice and significantly enhance the exercise capacity of doxorubicin-induced aging mice. At the same time, knockout of mPGES‑2 can significantly inhibit hydrogen peroxide-induced aging of primary mouse fibroblast MEFs and promote proliferation. These results indicate that knocking out mPGES‑2 can improve the senescence phenotype induced by doxorubicin, delay the natural aging of MEFs and the accelerated aging induced by hydrogen peroxide, and indicate that mPGES‑2 can be used as a preventive and / or therapeutic agent for doxorubicin and / or The targets of hydrogen peroxide-induced aging and aging-related diseases are of great significance for the development of drugs and the prevention and / or treatment of such diseases in the future.

The invention belongs to the technical field of molecular diagnostic medicine, and aims to solve the technical problem that a proper target spot and an intervention strategy cannot be provided under the situation that SIRT1 is used for evaluating molecular diagnosis of individual aging and aging-related diseases and delaying individual aging in the prior art. The invention provides application ofSIRT1-T177 locus phosphorylation as a biomarker to aging-related diseases. The SIRT1-T177 locus phosphorylation can be taken as a molecular marker for aging and related diseases, and can be taken as an intervention measure for delaying aging and related diseases; a novel target spot and a novel intervention strategy are provided for the molecular diagnosis of individual aging and aging-related diseases and delaying of individual aging are provided.

Disclosed is a use of E3 ligase FBW7 in preparing a drug for delaying aging and for preventing and treating aging-related diseases by means of inhibiting telomere damage, wherein the amino acid sequence of the FBW7 is as shown in SEQ. No.2. Knockout or RNA interference inhibiting the gene expression of the FBW7, a gene mutant expressing the FBW7 competitively inhibiting the FBW7 protein, or the overexpression of TPP1 overcoming the degradation caused by the FBW7 can protect the chromosome telomere from damage caused by stress, such as radiation, bleomycin and hydrogen peroxide, prevent the degradation of TPP1 in the basic state or in the stress state, result in the effect of extending telomere length, increase the number of tissue stem cells, improve the pulmonary respiratory function in the basic state, and prevent the occurrence of lung tissue aging and pulmonary fibrosis in the stress state, and same can be used in preparing a drug for preventing and treating telomere dysfunction to provide ideas and means for anti-aging.

The invention belongs to the field of biotechnology, and discloses a construct integrating the functions of senescent cell localization, tracing, sorting, inducing senescent cell apoptosis and / or clearing senescent cells, and cells or animals transformed by the construct Model. The construct functions by targeting the P21 gene in the genome and inserting it into its proper position. The cells or animal models obtained by the method of the present invention can be used to study aging and aging-related diseases.

The invention provides the application of ubiquitin protease USP7 in the preparation of medicines for preventing and treating aging-related diseases. The amino acid sequence of the ubiquitin protease USP7 is shown in SEQ.No.2. The invention activates USP7 enzyme, prevents telomere protein degradation and telomere damage, especially in environmental stress state such as radiation damage or oxidative stress caused by telomere protein degradation, and prevents telomere protein degradation caused by stress or stress hypoxia. Damage shortening, aging of tissues and organs and related diseases. Inhibit the expression or enzyme activity of USP7, prevent the protective effect of USP7 on telomere protein and telomere, cause telomere shortening and damage response, thereby causing tumor cell proliferation, growth inhibition and aging death, and can inhibit tumor development, growth, invasion and metastasis . It can be applied in the preparation of drugs for preventing and treating diseases related to telomere dysfunction, and the invention provides new ideas and means for anti-aging.

The invention discloses a method for predicting carotid artery aging based on elastic modulus. The method includes establishing a carotid artery aging model. The model uses the elastic modulus and intima-media thickness of the carotid artery as evaluation marks. The nonlinear relationship between age and carotid elastic modulus and intima-media thickness can be used to describe the aging process of cardiovascular with age. The variation law of the carotid intima-media thickness and elastic modulus of each age group described in the present invention is basically consistent with the data detected in relevant medical literature, showing that it is effective to express the relationship between aging and intima-media thickness with the segmented method The elastic modulus of the carotid artery is an objective index for evaluating cardiovascular aging, so this model can be used to assist in the analysis of the occurrence and development of cardiovascular aging and related diseases, and provides new ideas for the prevention and treatment of various aging-related diseases , opened up new horizons.